



FDA-Industry IVD Roundtable Meeting

Hosted by AMDM
Hogan Lovells
 555 Thirteenth St. NW
 Washington, DC 20004

Thursday, December 8, 2011
 9:00 AM - 3:30 PM

AGENDA

9:00 – 9:10 AM	Welcome and Introductions <i>Sheri Hall, IVD Roundtable Liaison, BD</i>
9:10 – 9:30 AM	Introductory Remarks: “Perspective Amidst Changing Times” <i>Jonathon Kahan, Hogan and Lovells</i>
9:30 – 10:10 AM	OIVD Update <i>Alberto Gutierrez, FDA/CDRH/OIVD</i> <ul style="list-style-type: none"> • OIVD 2012 Priorities and Updates • 510(k) Reform Implementation Update [e.g., 510(k) Modifications] • Class I/II IVD Exemptions • Regulation of Lab Developed Tests • October 13 Public Meeting re. Highly Multiplexed Microbiology/MCM Devices • Key Guidances
10:10 – 10:20 AM	Break
10:20 – 11:10 AM	DeNovo Classification Process Guidance: What’s New/How It Works and a Case Example Introduction of Presenters <i>Sheri Hall, BD</i> Presenters <i>April Veoukas, Abbott</i> <i>Melissa Burns, FDA/CDRH/ODE</i>

11:10 AM – 12:00 PM	<p>Panel Session: Developments in Personalized Medicine: In Vitro Companion Diagnostics Guidance</p> <p>Introduction of Presenters <i>Robert DiTullio, Alere</i></p> <p>Panel Discussion <i>Eric Lawson, Voison Consulting, AMDM Companion Diagnostics Working Group</i> <i>William Pignato, AdvaMed Personalized Medicine and Molecular Diagnostics Working Group, Novartis</i> <i>Andrew Dayton, FDA/CBER/OBRR</i> <i>Elizabeth Mansfield, FDA/CDRH/OIVD/FDA</i></p>
12:00 – 1:00 PM	Lunch
1:00 – 1:45 PM	<p>Research Use Only <i>James Kelly, AdvaMed Diagnostics Task Force, Affymetrix</i> <i>Katherine Serrano, FDA/CDRH/OIVD</i></p>
1:45 – 2:30 PM	<p>CBER Update <i>Sayah Nedjar, FDA/CBER/OBRR</i></p> <ul style="list-style-type: none"> • CBER 2012 Priorities and Updates • Key Guidances
2:30 – 3:15 PM	<p>Regulatory Considerations for HLA Test Kits <i>Annette Ragosta, FDA/CBER/OBRR</i></p>
3:15 – 3:30 PM	New Business and Next Meeting